Natco slumps on Teva's Copaxone appeal

Reuters Market Eye - Shares in Natco Pharma falls 13 percent, heading towards their biggest ever single-day fall after the U.S. Supreme Court on Monday agreed to hear an appeal filed by Teva Pharmaceutical Industries Ltd in a patent fight over top-selling multiple sclerosis drug Copaxone.

The appeal could deter generic manufacturers such as Natco from introducing cheaper versions of Capaxone onto the market as soon as May.

The company continues to believe that Teva's patent on Copaxone is "invalid," the company said in a filing to the exchange.

Natco shares had earlier fallen as much as 18.6 percent.

(Reporting by Abhishek Vishnoi)